Sacituzumab Govitecan-hziy was approved in 2020, a
Post# of 154560
(Total Views: 542)
Posted On: 04/24/2025 10:11:57 AM
Sacituzumab Govitecan-hziy was approved in 2020, and people still have cancer.
So I asked my friend ChatGPT her thoughts.
Leronlimab and Sacituzumab Govitecan-hziy are biologic drugs used in different therapeutic areas, but they differ in several fundamental ways—mechanism of action, target, indications, and molecular structure. Here's a breakdown of their differences:
1. Drug Class & Type
Leronlimab:
Type: Humanized monoclonal antibody.
Target: CCR5 receptor.
Class: CCR5 antagonist.
Sacituzumab Govitecan-hziy (Trodelvy):
Type: Antibody-drug conjugate (ADC).
Target: Trop-2 protein.
Payload: SN-38 (an active metabolite of irinotecan, a topoisomerase I inhibitor).
Class: Targeted cytotoxic chemotherapy.
2. Mechanism of Action
Leronlimab:
Blocks the CCR5 receptor, which is involved in HIV entry into cells and in modulating immune responses (in some cancers and inflammatory diseases).
It prevents HIV from binding to CCR5 and entering immune cells.
It has also been studied in cancer and COVID-19 for its role in modulating the immune system.
Sacituzumab Govitecan-hziy:
Binds to Trop-2, which is overexpressed in various cancers.
After internalization, the ADC releases SN-38, a cytotoxic agent that kills cancer cells by inhibiting topoisomerase I, leading to DNA damage and apoptosis.
3. Approved or Investigational Uses
Leronlimab (investigational; not FDA-approved):
Initially developed for HIV treatment.
Investigated for metastatic triple-negative breast cancer (TNBC), COVID-19, and NASH.
Sacituzumab Govitecan-hziy (Trodelvy) (FDA-approved):
Approved for metastatic triple-negative breast cancer (mTNBC).
Also approved for HR+/HER2- breast cancer and under investigation for other solid tumors.
4. Delivery
Leronlimab:
Administered via subcutaneous injection.
Sacituzumab Govitecan-hziy:
Administered via intravenous infusion.
5. Side Effect Profiles
Leronlimab:
Generally well tolerated in HIV studies. Some adverse effects in cancer/COVID-19 trials due to immune modulation.
Sacituzumab Govitecan-hziy:
Typical chemotherapy-related side effects such as neutropenia, diarrhea, nausea, and fatigue, mostly from the SN-38 payload.
Summary:
Feature Leronlimab Sacituzumab Govitecan-hziy
Type Monoclonal antibody Antibody-drug conjugate
Target CCR5 Trop-2
Mechanism Blocks HIV/cancer cell entry Delivers cytotoxic SN-38 to cancer cells
Main Use Investigational (HIV, cancer, COVID) Approved for mTNBC & HR+/HER2- breast cancer
Route Subcutaneous Intravenous
Side Effects Immune-related Chemotherapy-like
Would you like a visual comparison chart or details on their clinical trial outcomes?
You said:
Yes
ChatGPT said:
Great! Here's a visual comparison chart between Leronlimab and Sacituzumab Govitecan-hziy for easier side-by-side reference:
???? Leronlimab vs Sacituzumab Govitecan-hziy (Trodelvy)
Feature Leronlimab Sacituzumab Govitecan-hziy (Trodelvy)
Drug Class Monoclonal antibody Antibody-drug conjugate (ADC)
Target CCR5 receptor (chemokine receptor) Trop-2 (tumor-associated calcium signal transducer)
Mechanism of Action Blocks CCR5 to prevent viral/cancer cell entry & modulate immune response Delivers SN-38 (cytotoxic payload) to Trop-2 expressing cancer cells
Primary Use Investigational: HIV, COVID-19, metastatic cancers FDA-approved: mTNBC, HR+/HER2- breast cancer
FDA Approval Status Not FDA-approved (under investigation) FDA-approved
Route of Administration Subcutaneous injection Intravenous infusion
Payload None – direct receptor blockade SN-38 (topoisomerase I inhibitor)
Side Effects Mild to moderate; mostly immune-modulation related Chemo-like: neutropenia, diarrhea, nausea, fatigue
Development Company CytoDyn Inc. Gilead Sciences
Key Indications (in trials) HIV, COVID-19, mTNBC, NASH mTNBC, HR+/HER2- breast cancer, bladder cancer, other solid tumors (ongoing)
???? Clinical Trial Highlights (as of latest data):
Leronlimab
HIV: Shown promise in reducing viral loads as a CCR5 antagonist.
Cancer (e.g., mTNBC): Investigated for blocking metastasis via CCR5 pathway modulation. Mixed results; further data needed.
COVID-19: Explored for reducing cytokine storm. Results were inconclusive or not statistically significant in key trials.
Sacituzumab Govitecan-hziy
ASCENT Trial (mTNBC): Showed significant improvement in progression-free survival and overall survival vs chemotherapy.
HR+/HER2- Breast Cancer: Recent FDA approval based on TROPiCS-02 trial.
Being tested in a range of cancers including bladder, lung, and GI cancers.
So I asked my friend ChatGPT her thoughts.
Leronlimab and Sacituzumab Govitecan-hziy are biologic drugs used in different therapeutic areas, but they differ in several fundamental ways—mechanism of action, target, indications, and molecular structure. Here's a breakdown of their differences:
1. Drug Class & Type
Leronlimab:
Type: Humanized monoclonal antibody.
Target: CCR5 receptor.
Class: CCR5 antagonist.
Sacituzumab Govitecan-hziy (Trodelvy):
Type: Antibody-drug conjugate (ADC).
Target: Trop-2 protein.
Payload: SN-38 (an active metabolite of irinotecan, a topoisomerase I inhibitor).
Class: Targeted cytotoxic chemotherapy.
2. Mechanism of Action
Leronlimab:
Blocks the CCR5 receptor, which is involved in HIV entry into cells and in modulating immune responses (in some cancers and inflammatory diseases).
It prevents HIV from binding to CCR5 and entering immune cells.
It has also been studied in cancer and COVID-19 for its role in modulating the immune system.
Sacituzumab Govitecan-hziy:
Binds to Trop-2, which is overexpressed in various cancers.
After internalization, the ADC releases SN-38, a cytotoxic agent that kills cancer cells by inhibiting topoisomerase I, leading to DNA damage and apoptosis.
3. Approved or Investigational Uses
Leronlimab (investigational; not FDA-approved):
Initially developed for HIV treatment.
Investigated for metastatic triple-negative breast cancer (TNBC), COVID-19, and NASH.
Sacituzumab Govitecan-hziy (Trodelvy) (FDA-approved):
Approved for metastatic triple-negative breast cancer (mTNBC).
Also approved for HR+/HER2- breast cancer and under investigation for other solid tumors.
4. Delivery
Leronlimab:
Administered via subcutaneous injection.
Sacituzumab Govitecan-hziy:
Administered via intravenous infusion.
5. Side Effect Profiles
Leronlimab:
Generally well tolerated in HIV studies. Some adverse effects in cancer/COVID-19 trials due to immune modulation.
Sacituzumab Govitecan-hziy:
Typical chemotherapy-related side effects such as neutropenia, diarrhea, nausea, and fatigue, mostly from the SN-38 payload.
Summary:
Feature Leronlimab Sacituzumab Govitecan-hziy
Type Monoclonal antibody Antibody-drug conjugate
Target CCR5 Trop-2
Mechanism Blocks HIV/cancer cell entry Delivers cytotoxic SN-38 to cancer cells
Main Use Investigational (HIV, cancer, COVID) Approved for mTNBC & HR+/HER2- breast cancer
Route Subcutaneous Intravenous
Side Effects Immune-related Chemotherapy-like
Would you like a visual comparison chart or details on their clinical trial outcomes?
You said:
Yes
ChatGPT said:
Great! Here's a visual comparison chart between Leronlimab and Sacituzumab Govitecan-hziy for easier side-by-side reference:
???? Leronlimab vs Sacituzumab Govitecan-hziy (Trodelvy)
Feature Leronlimab Sacituzumab Govitecan-hziy (Trodelvy)
Drug Class Monoclonal antibody Antibody-drug conjugate (ADC)
Target CCR5 receptor (chemokine receptor) Trop-2 (tumor-associated calcium signal transducer)
Mechanism of Action Blocks CCR5 to prevent viral/cancer cell entry & modulate immune response Delivers SN-38 (cytotoxic payload) to Trop-2 expressing cancer cells
Primary Use Investigational: HIV, COVID-19, metastatic cancers FDA-approved: mTNBC, HR+/HER2- breast cancer
FDA Approval Status Not FDA-approved (under investigation) FDA-approved
Route of Administration Subcutaneous injection Intravenous infusion
Payload None – direct receptor blockade SN-38 (topoisomerase I inhibitor)
Side Effects Mild to moderate; mostly immune-modulation related Chemo-like: neutropenia, diarrhea, nausea, fatigue
Development Company CytoDyn Inc. Gilead Sciences
Key Indications (in trials) HIV, COVID-19, mTNBC, NASH mTNBC, HR+/HER2- breast cancer, bladder cancer, other solid tumors (ongoing)
???? Clinical Trial Highlights (as of latest data):
Leronlimab
HIV: Shown promise in reducing viral loads as a CCR5 antagonist.
Cancer (e.g., mTNBC): Investigated for blocking metastasis via CCR5 pathway modulation. Mixed results; further data needed.
COVID-19: Explored for reducing cytokine storm. Results were inconclusive or not statistically significant in key trials.
Sacituzumab Govitecan-hziy
ASCENT Trial (mTNBC): Showed significant improvement in progression-free survival and overall survival vs chemotherapy.
HR+/HER2- Breast Cancer: Recent FDA approval based on TROPiCS-02 trial.
Being tested in a range of cancers including bladder, lung, and GI cancers.
(5)
(0)